When suicidal thoughts become a psychiatric emergency, waiting weeks for traditional antidepressants may not be enough. A new Stanford study explores an emerging rapid-intervention strategy using IV ketamine followed by low-dose buprenorphine to help sustain anti-suicidal effects in patients with major depression. Here’s what the science says—and why this could represent a meaningful shift in interventional psychiatry.

Agitation and hyperarousal are among the most distressing symptoms of Alzheimer’s disease—impacting patients, caregivers, and overall quality of life.

Until recently, treatment options were limited and often relied on off-label use of antipsychotics, which carry significant risks in older adults.

Now, a novel approach is emerging: Auvelity (dextromethorphan–bupropion) is gaining attention—and has received recent FDA approval for agitation in Alzheimer’s disease—marking a major shift in treatment strategy.

Brain fog, sleep disruption, chronic stress Reno, NV